ALKS today
$47.89+$1.42 (+3.06%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourExpanding
1 hourStrong Bullish
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns down below $38.98
Key levels
Resistance$51.66
Resistance$48.73
Support$46.38
Support$44.07
Latest news & SEC filings
AnalystRBC nudges Alkermes target up to $57
AnalystRBC Capital keeps Outperform on Alkermes, lifts target to $57
AnalystWells Fargo keeps Overweight on Alkermes, lifts target to $68
All ALKS news →About Alkermes
Alkermes is a biopharmaceutical company that develops and commercializes medicines for central nervous system disorders such as schizophrenia, bipolar disorder, addiction, and multiple sclerosis. It sells proprietary products including LYBALVI, ARISTADA, and LUMRYZ, and earns royalties and manufacturing revenue from licensed products made with its proprietary drug-delivery technologies, such as long-acting injectables. Its customers include physicians, patients, pharmacies, and government and commercial payers, primarily in the United States, with additional operations in Ireland and other markets.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
Alkermes plc. (ALKS)
What Is the Price Target for ALKS?
SEPT Low Target
$38.00
SEPT Mid Target
$56.00
SEPT High Target
$65.00
Analyst Consensus
$56.00
Is ALKS a Buy or Sell Right Now?
Thesis
- •Revenue growing -5.2% YoY with STABLE trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALKS.
Start Free Trial →Is ALKS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$48.61
27
Moat Score
NONE
6/9
Piotroski Score
8.1
Altman Z-Score
What Is Smart Money Doing with ALKS?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
BUYING
3 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Gaffin David Joseph | officer | Sale | 2,035 | $94K | Nov 3, 2026 |
| Reed Joshua | officer | Buy | 9,164 | - | Oct 8, 2026 |
| Reed Joshua | officer | Sale | 4,069 | $163K | Oct 8, 2026 |
| Hopkinson Craig C. | officer | Buy | 5,000 | $123K | Sep 1, 2026 |
| Hopkinson Craig C. | officer | Sale | 9,000 | $423K | Sep 1, 2026 |
| Wright Christopher I | director | Sale | 2,000 | $90K | Jun 12, 2026 |
| Gaffin David Joseph | officer | Sale | 2,034 | $88K | Jun 4, 2026 |
| Hopkinson Craig C. | officer | Buy | 5,000 | $97K | Jun 1, 2026 |
| Hopkinson Craig C. | officer | Sale | 9,000 | $375K | Jun 1, 2026 |
| Parisi Samuel Joseph | officer | Buy | 3,392 | $68K | May 29, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALKS Growth Story
Revenue YoY
-5.3%
3yr Revenue CAGR
9.9%
EPS Growth YoY
-34.1%
FCF Growth YoY
18.4%
Revenue Trend
STABLE
Dark Pool Trades for ALKS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALKS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:45 | $47.89 | 14,153 | $$678K | BUY |
| 21:00:33 | $47.89 | 1,086 | $$52K | BUY |
| 21:00:33 | $47.89 | 3,600 | $$172K | BUY |
| 20:45:27 | $47.88 | 8,980 | $$430K | SELL |
| 20:40:10 | $47.90 | 1,200 | $$57K | BUY |
5 dark pool trades shown · $$1.4M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Alkermes plc. (ALKS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALKS — frequently asked questions
What is ALKS stock price today?
Alkermes plc. (ALKS) is at $47.89, up 3.06% (+$1.42) at the Nov 11, 2026 close.
Why is ALKS stock moving today?
Latest ALKS news — Nov 4, 2026: RBC nudges Alkermes target up to $57 · Nov 4, 2026: RBC Capital keeps Outperform on Alkermes, lifts target to $57
What is the ALKS price target?
The average analyst price target for ALKS is $56.00, ranging from $38 to $65, based on 9 analysts.
What do analysts rate ALKS?
Analyst ratings for ALKS: 0 Buy, 16 Hold, 1 Sell — consensus Hold.
Did ALKS beat earnings?
ALKS last reported on Jul 28, 2026: EPS $0.70 vs -$0.03 expected — a beat of 2645.5%.
What is ALKS's P/E ratio?
ALKS trades at a P/E of 118.1 vs a Healthcare average of 17.6.
Does ALKS pay a dividend?
ALKS does not currently pay a dividend.
How much debt does ALKS have?
Alkermes plc. reported $1.5B of debt and $512M of cash (Jun 30, 2026).
What are ALKS support and resistance levels?
Support: $46.38, $44.07, $42.19. Resistance: $48.73, $51.66, $53.88.
What are insiders doing with ALKS?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on ALKS?
Nov 4, 2026: RBC nudges Alkermes target up to $57 · Nov 4, 2026: RBC Capital keeps Outperform on Alkermes, lifts target to $57 · Nov 4, 2026: Wells Fargo keeps Overweight on Alkermes, lifts target to $68